Tourmaline Bio
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Tourmaline Bio generated cash of -$28,081,000, which is less than the previous year. Cash used in financing activities reached the amount of $156,720,000 last year. Net change in cash is therefore $132,479,000.
Cash Flow
| 2019 | -17.66M | -562K | 36.20M |
|---|---|---|---|
| 2022 | -6.45M | -5.06M | 19.85M |
| 2023 | -28.08M | 3.84M | 156.72M |
TRML Cash Flow Statement (2019 – 2023)
| 2023 | 2022 | 2019 | |
|---|---|---|---|
Cash at beginning of period | 8.47M | 150K | 20.99M |
Operating activities | |||
Net income | -42.12M | -19.70M | -18.15M |
| Adjustments to reconcile net income to cash generated by operating activities: | |||
Depreciation and amortization | 33K | 6K | 379K |
Stock-based compensation expense | 5.76M | 195K | 0 |
| Deferred income tax benefit | 5.76M | 195K | 0 |
| Changes in operating assets and liabilities: | |||
Accounts receivable, net | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 |
Accounts payable | -44K | 193K | 0 |
Cash generated by operating activities | -28.08M | -6.45M | -17.66M |
Investing activities | |||
Purchases Of Investments | -16.60M | 0 | 0 |
Investments In Property Plant And Equipment | -56K | -5.06M | -562K |
Acquisitions Net | 0 | -5M | 0 |
Cash generated by investing activities | 3.84M | -5.06M | -562K |
Financing activities | |||
Common Stock Issued | 70.46M | 20M | 36.20M |
Payments for dividends | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 |
Repayments of term debt | 0 | 0 | 0 |
Cash used in financing activities | 156.72M | 19.85M | 36.20M |
Net Change In Cash | 132.47M | 8.32M | 17.98M |
Cash at end of period | 140.95M | 8.47M | 38.97M |
| Data source |